Alto Neuroscience, Inc. (NYSE:ANRO) Short Interest Update

Alto Neuroscience, Inc. (NYSE:ANRO) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 4,080,000 shares, a decrease of 12.4% from the November 15th total of 4,660,000 shares. Currently, 18.6% of the company’s stock are short sold. Based on an average daily volume of 777,200 shares, the short-interest ratio is presently 5.2 days.

Wall Street Analyst Weigh In

ANRO has been the subject of a number of research analyst reports. Rodman & Renshaw lowered shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Robert W. Baird reduced their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Finally, Stifel Nicolaus reduced their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 13th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Federated Hermes Inc. increased its holdings in shares of Alto Neuroscience by 33.3% during the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after purchasing an additional 3,000 shares during the period. BNP Paribas Financial Markets increased its holdings in shares of Alto Neuroscience by 619.2% during the third quarter. BNP Paribas Financial Markets now owns 4,315 shares of the company’s stock worth $49,000 after purchasing an additional 3,715 shares during the period. Philadelphia Financial Management of San Francisco LLC increased its holdings in shares of Alto Neuroscience by 1.5% during the third quarter. Philadelphia Financial Management of San Francisco LLC now owns 449,952 shares of the company’s stock worth $5,147,000 after purchasing an additional 6,663 shares during the period. Rhumbline Advisers bought a new position in shares of Alto Neuroscience during the second quarter worth approximately $113,000. Finally, Jane Street Group LLC bought a new position in shares of Alto Neuroscience during the third quarter worth approximately $124,000.

Alto Neuroscience Stock Performance

Alto Neuroscience stock traded up $0.04 during trading hours on Tuesday, hitting $3.79. The company had a trading volume of 342,881 shares, compared to its average volume of 370,987. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. Alto Neuroscience has a one year low of $3.58 and a one year high of $24.00. The firm has a 50-day moving average of $6.21 and a 200 day moving average of $9.92.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.05. As a group, equities research analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.